Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems

Table 8

Levodopa noncompartmental pharmacokinetic parameters following oral administration of Madopar HBS capsules, PXLNET, and IPB matrices.

Pharmacokinetic parameter	Madopar HBS	PXLNET	IPB
(h)	2	2	4
(ng/mL)	372.37	257.02	461.28
(ng/mLh)	2816.47	2121.43	3347.45
(ng/mLh)	3685.03	2722.42	4147.16
(ng/mL(h)^2)	56590.17	40775.35	55147.93
MRT (h)	15.36	14.98	13.30
Vz/F [mg/(ng/mL)]	0.3598	0.4847	0.2874
Cl/F [mg/(ng/mL)/h]	0.0271	0.0367	0.0241

, time for maximum concentration of drug; , maximum drug concentration; , area under the concentration-time curve; , area under the concentration-time curve from time 0 to infinity; , area under the first moment of concentration-time curve from time 0 to infinity; MRT, mean residence time. Cl/F is apparent clearance and Vz/F is apparent volume of distribution.